Scancell logo

Scancell

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer.

57 employees · est. 1996 · Oxford, United Kingdom

VS
SynOx Therapeutics logo

SynOx Therapeutics

Our mission is to focus on the unmet clinical needs of patients  suffering from Tenosynovial Giant Cell Tumours (TGCT)

29 employees · est. 2020 · Ireland

Scancell is the older company (1996 vs 2020); Scancell is the larger of the two.

Side-by-Side Comparison

Scancell SynOx Therapeutics
Founded
1996 older 2020
Headquarters
Oxford, United Kingdom Ireland
Employees
57 larger 29
Industry
Biotechnology, Health Care Biotechnology, Health and Wellness
Funding Stage
Post Ipo Equity Debt Financing
Total Funding
$15.65M $147.00M
Funding Rounds
5 3
Services
Not tracked yet Development of emactuzumab, Treatment of TGCT, Macrophage-mediated disease solutions
Target Customers
Not tracked yet Patients with TGCT, Healthcare Providers, Biotech Researchers
Taxonomy
Immunology, Cancer, ImmunoBody, Moditope, Cancer Vaccines, AvidiMab, GlyMab, Antibody Platforms, Tumours, Immune System, Cancer Treatment, Prevention, Biopharmaceuticals Research, Emactuzumab, TGCT Treatment, Tenosynovial Giant Cell Tumours, Diffuse Tumours, Biopharma Development, Clinical Needs, Therapeutic Development, Investor-backed, Biopharmaceuticals, Tumour Treatment, Health Innovation
Website
scancell.co.uk synoxtherapeutics.com
Scancell logo

About Scancell

Scancell Ltd is a UK-based startup dedicated to using immunology to fight cancer. Established in 1996, the company focuses on developing innovative products that stimulate the immune system to treat or prevent cancer. Operating in the biotechnology and healthcare industries, Scancell aims to address...

SynOx Therapeutics logo

About SynOx Therapeutics

SynOx Therapeutics, an innovative player in the Biotechnology and Health and Wellness sectors, is strategically positioned to address critical needs in cancer treatment. Founded in November 2020, this Ireland-based company is committed to developing emactuzumab for the treatment of diffuse tenosynov...

We will tell you when either one moves

BounceWatch watches Scancell and SynOx Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Scancell and SynOx Therapeutics — by email.

Frequently Asked Questions

Scancell — Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. . SynOx Therapeutics — Our mission is to focus on the unmet clinical needs of patients  suffering from Tenosynovial Giant Cell Tumours (TGCT). Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Scancell has raised $15.65M while SynOx Therapeutics has raised $147.00M.
Scancell and SynOx Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Scancell with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Scancell on 12 Sep 2024, and SynOx Therapeutics on 18 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy